PharmaEssentia Corporation (TPE:6446)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
475.50
+22.00 (4.85%)
Nov 20, 2025, 1:35 PM CST

PharmaEssentia Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
175,863204,725114,578143,84078,06524,709
Upgrade
Market Cap Growth
-17.56%78.68%-20.34%84.26%215.94%2.44%
Upgrade
Enterprise Value
155,174184,91594,836140,32277,60321,027
Upgrade
Last Close Price
475.50552.99311.12428.91260.1783.29
Upgrade
PE Ratio
36.7269.04----
Upgrade
Forward PE
25.4641.3631.8969.03--
Upgrade
PS Ratio
12.7321.0322.4449.91118.9144.34
Upgrade
PB Ratio
5.917.454.7811.8518.376.30
Upgrade
P/TBV Ratio
5.967.534.8412.0819.506.68
Upgrade
P/FCF Ratio
58.13121.51----
Upgrade
P/OCF Ratio
40.7680.38----
Upgrade
EV/Sales Ratio
11.2319.0018.5848.69118.2137.73
Upgrade
EV/EBITDA Ratio
36.50100.14----
Upgrade
EV/EBIT Ratio
39.73106.51----
Upgrade
EV/FCF Ratio
51.29109.75----
Upgrade
Debt / Equity Ratio
0.030.040.050.130.130.17
Upgrade
Debt / EBITDA Ratio
0.210.47----
Upgrade
Debt / FCF Ratio
0.300.57----
Upgrade
Asset Turnover
0.430.330.240.270.110.13
Upgrade
Inventory Turnover
1.220.860.480.830.601.15
Upgrade
Quick Ratio
6.459.349.864.372.803.37
Upgrade
Current Ratio
6.839.9410.645.243.493.82
Upgrade
Return on Equity (ROE)
17.21%11.54%-3.46%-16.77%-68.81%-63.10%
Upgrade
Return on Assets (ROA)
7.68%3.72%-5.61%-11.77%-30.08%-25.26%
Upgrade
Return on Capital (ROIC)
8.46%4.05%-6.16%-13.71%-37.72%-29.60%
Upgrade
Return on Capital Employed (ROCE)
12.80%6.10%-7.60%-15.90%-59.00%-38.60%
Upgrade
Earnings Yield
2.73%1.45%-0.54%-0.96%-3.60%-7.88%
Upgrade
FCF Yield
1.72%0.82%-1.74%-1.26%-3.24%-6.22%
Upgrade
Dividend Yield
0.22%0.18%----
Upgrade
Buyback Yield / Dilution
-0.44%-3.59%-13.47%-9.24%-7.39%-10.55%
Upgrade
Total Shareholder Return
-0.22%-3.41%-13.47%-9.24%-7.39%-10.55%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.